Los Angeles, CA, United States of America

Silvia Senese

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: University of California. Active years: 2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Silvia Senese. Retrieved from https://idiyas.com/inventor/silvia-senese

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Silvia Senese: Innovator in Cancer Treatment

Introduction

Silvia Senese is a prominent inventor based in Los Angeles, CA. She has made significant contributions to the field of cancer treatment through her innovative research and development of new therapeutic methods.

Latest Patents

Silvia holds 1 patent for her work on tubulin-binding compounds, compositions, and their related uses. This patent specifically addresses methods of treating cancer, including melanoma, utilizing a compound known as MI-181.

Career Highlights

Silvia is affiliated with the University of California, where she continues to advance her research in oncology. Her work has garnered attention for its potential impact on cancer therapies.

Collaborations

Some of her notable coworkers include Robert Damoiseaux and Jorge Torres, who contribute to her research efforts and collaborative projects.

Conclusion

Silvia Senese's innovative work in cancer treatment exemplifies the vital role of inventors in advancing medical science. Her contributions are paving the way for new therapeutic options in oncology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…